I lead the Renal Research Group within the College of Life Sciences, University of Leicester. I am the IgA nephropathy Rare Disease Group lead for the UK National Registry of Rare Kidney Diseases (RaDaR) and a member of the steering committee for the International IgA Nephropathy Network. I work closely with a number of pharmaceutical companies interested in new treatments for IgA nephropathy. I am Chief Investigator for a number of international randomised controlled clinical trials in IgA nephropathy, have attended both the FDA and EMA as an advisor for new therapies in IgA nephropathy, and am a member of the FDA and American Society of Nephrology Kidney Health Initiative: Identifying Surrogate Endpoints for Clinical Trials in IgA Nephropathy Workgroup. I am an Editorial Board member for Kidney International and Clinical Journal of the American Society of Nephrology and sit on the Kidney Research UK Grants Committee. I am a member of the Renal GeCIP (Genomics England Clinical Interpretation Partnerships) and UK Glomerulonephritis Clinical Study Group.

I provide advice concerning new drug development in kidney disease providing advice on preclinical data, clinical trial protocol development, regulatory pathways and new therapeutic opportunities.